Sign up to save your podcasts
Or
Share Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Rapid, high-sensitivity ADAMTS13 assays for TTP; combination CD38/PD-1 blockade in extranodal NK/T-cell lymphoma; a “zombie enzyme” in CREBBP-mutant lymphomas
In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable responses and manageable safety. Finally, a lymphoma horror story with a happy ending. CREBBP mutations create a zombie enzyme that competes with its wild-type counterparts. By enforcing CD40 signaling, a bispecific antibody overcomes this effect and induces lymphoma cell death.
Featured Articles:
- Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
- Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
- Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement
View all episodes
By American Society of Hematology
4.1
4848 ratings
In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable responses and manageable safety. Finally, a lymphoma horror story with a happy ending. CREBBP mutations create a zombie enzyme that competes with its wild-type counterparts. By enforcing CD40 signaling, a bispecific antibody overcomes this effect and induces lymphoma cell death.
Featured Articles:
- Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
- Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
- Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement
More shows like Blood Podcast
View all
JAMA Editors' Summary
133 Listeners
NEJM This Week
315 Listeners
The Hematologist
26 Listeners
JAMA Clinical Reviews
488 Listeners
JAMA Medical News
91 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
VJHemOnc Podcast
3 Listeners
Annals On Call Podcast
191 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
The BSH Guidelines Official Podcast
1 Listeners
EHA Unplugged
1 Listeners
WolverHeme Happy Hour
28 Listeners
Two Onc Docs
169 Listeners
Blood Cancer Talks
49 Listeners
HemeTalks: Conversations in Hematology Education
3 Listeners